NHS Grampian
Formulary Group Decisions for SMC advice published April 2019 to March 2020

This document summarises the decisions of the NHS Grampian Formulary Group for Scottish Medicines Consortium (SMC) advice published April 2019 to March 2020.

For the latest Formulary Group decisions see the Grampian Area Formulary website.

March 2023

Image courtesy of Baitong333 - image ID: 100128772/ FreeDigitalPhotos.net

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
abemaciclib 50mg, 100mg, 150mg tablets (Verzenios®)	2135	For the treatment of women with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor* as initial endocrine-based therapy, or in women who have received prior endocrine therapy. *For SMC advice relating to the use of abemaciclib in combination with fulvestrant in this setting, please refer to SMC 2179.	Routinely available in line with national guidance, SMC 2135 https://www.scottishmedicines.org.uk/media/4377/abemaciclib-verzenios-final-april-2019-1-for-website.pdf Updates decision 21/05/19	19/11/2019
abemaciclib 50mg, 100mg, 150mg tablets (Verzenios®)	2179	For the treatment of women with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer in combination with fulvestrant* as initial endocrine-based therapy or in women who have received prior endocrine therapy. **SMC restriction:** for use in women who have progressed on or after (neo) adjuvant endocrine therapy, or progressed during first-line endocrine-based therapy for advanced breast cancer. * For SMC advice relating to the use of abemaciclib in combination with an aromatase inhibitor in this setting, please refer to SMC 2135.	Routinely available in line with national guidance, SMC 2179 https://www.scottishmedicines.org.uk/media/4378/abemaciclib-verzenios-final-april-2019-2-for-website.pdf Updates decision 21/05/19	19/11/2019
abiraterone acetate 500mg film-coated tablets (Zytiga®)	2215	Abiraterone acetate with prednisone or prednisolone for the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer in adult men in combination with androgen deprivation therapy.	Routinely available in line with national guidance, SMC 2215 https://www.scottishmedicines.org.uk/media/4979/abiraterone-zytiga-final-december-2019-amended-181219-for-website.pdf Updates decision 21/01/20	20/10/2020

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
alirocumab 75mg , 150mg solution for injection in pre-filled pen (Praluent®)	2201	In adults with established atherosclerotic cardiovascular disease to reduce cardiovascular risk by lowering LDL-C levels, as an adjunct to correction of other risk factors: - in combination with the maximum tolerated dose of a statin with or without other lipid-lowering therapies or, - alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated.	Not routinely available as not recommended for use in NHS Scotland, SMC 2201 https://www.scottishmedicines.org.uk/media/4451/alirocumab-praluent-non-sub-final-may-2019-for-website.pdf	18/06/2019
apalutamide 60mg film-coated tablets (Erleada®)	2268	In adult men for the treatment of non-metastatic castration-resistant prostate cancer (NM-CRPC) who are at high risk of developing metastatic disease.	Not routinely available as not recommended for use in NHS Scotland, SMC 2268 https://www.scottishmedicines.org.uk/media/5056/apalutamide-erleada-non-sub-final-jan-2020-for-website.pdf	18/02/2020
arsenic trioxide 1mg/mL concentrate for solution for infusion (Trisenox®)	2181	In combination with all-*trans* -retinoic acid (ATRA [tretinoin]) for the induction of remission, and consolidation in adult patients with newly diagnosed, low-to-intermediate risk acute promyelocytic leukaemia (APL) (white blood cell count ≤10 x 10^3/µl), characterised by the presence of the t(15;17) translocation and/or the presence of the Pro Myelocytic Leukaemia/Retinoic-Acid-Receptor-alpha (PML/RAR-alpha) gene.	Not routinely available as there is a local preference for alternative medicines Updates decision 16/07/19	20/10/2020

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
atezolizumab 1,200mg concentrate for solution for infusion (Tecentriq®)	2208	In combination with bevacizumab, paclitaxel and carboplatin, for the first-line treatment of adult patients with metastatic non-squamous non-small cell lung cancer (NSCLC). In patients with epidermal growth factor receptor (EGFR) mutant or anaplastic lymphoma kinase (ALK)-positive NSCLC, atezolizumab in combination with bevacizumab, paclitaxel and carboplatin, is indicated only after failure of appropriate targeted therapies.	Not routinely available as not recommended for use in NHS Scotland, SMC 2208 https://www.scottishmedicines.org.uk/media/4879/atezolizumab-tecentriq-final-october-2019-for-website.pdf	19/11/2019
atezolizumab 1,200mg concentrate for solution for infusion (Tecentriq®)	2254	In combination with nab-paclitaxel and carboplatin for the first-line treatment of adult patients with metastatic non-squamous non-small cell lung cancer (NSCLC) who do not have EGFR mutant or ALK-positive NSCLC.	Not routinely available as not recommended for use in NHS Scotland, SMC 2254 https://www.scottishmedicines.org.uk/media/4945/atezolizumab-tecentriq-non-sub-final-november-2019-for-website.pdf	17/12/2019
axicabtagene ciloleucel 0.4 – 2 x 10^8 cells dispersion for infusion (Yescarta®)	2189	Treatment of adult patients with relapsed or refractory diffuse large B cell lymphoma (DLBCL) and primary mediastinal large B cell lymphoma (PMBCL), after two or more lines of systemic therapy.	Routinely available from a specialist centre in another health board	19/11/2019
benralizumab 30mg solution for injection in pre filled syringe (Fasenra®)	2155	As an add-on maintenance treatment in adult patients with severe eosinophilic asthma inadequately controlled despite high-dose inhaled corticosteroids plus long-acting beta-agonists. **SMC restriction:** patients with blood eosinophils ≥150 cells/microlitre, and either ≥4 prior asthma exacerbations needing systemic corticosteroids in the previous 12 months or treatment with continuous oral corticosteroids over the previous 6 months.	Routinely available in line with national guidance, SMC 2155 https://www.scottishmedicines.org.uk/media/4447/benralizumab-fasenra-final-may-2019-amended-030619-for-website.pdf Updates decision 18/06/19	21/07/2020

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
blinatumomab 38.5micrograms powder for concentrate and solution for infusion (Blincyto®)	2148	As monotherapy for the treatment of paediatric patients aged 1 year or older with Philadelphia chromosome negative CD19 positive B-cell precursor acute lymphoblastic leukaemia which is refractory or in relapse after receiving at least two prior therapies or in relapse after receiving prior allogeneic hematopoietic stem cell transplantation.	Routinely available in line with national guidance, SMC 2148 https://www.scottishmedicines.org.uk/media/4315/blinatumomab-blincyto-abbreviated-final-march-2019-for-website.pdf	16/04/2019
blinatumomab 38.5micrograms powder for concentrate and solution for infusion (Blincyto®)	2234	As monotherapy for the treatment of adults with Philadelphia chromosome negative, CD19 positive, B-precursor acute lymphoblastic leukaemia (ALL) in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1%. **SMC restriction:** to patients who are in first complete remission with minimal residual disease (MRD) greater than or equal to 0.1%.	Routinely available in line with national guidance, SMC 2234 https://www.scottishmedicines.org.uk/media/5143/blinatumomab-blincyto-final-february-2020-for-website.pdf Updates decision 17/03/20	15/09/2020
brentuximab vedotin 50mg powder for concentrate for solution for infusion (Adcetris®)	2202	Treatment of adult patients with previously untreated CD30+ Stage IV Hodgkin lymphoma in combination with doxorubicin, vinblastine and dacarbazine (AVD).	Not routinely available as not recommended for use in NHS Scotland, SMC 2202 https://www.scottishmedicines.org.uk/media/4448/brentuximab-vedoten-adcetris-non-sub-final-may-2019-for-website.pdf	18/06/2019
brentuximab vedotin 50mg powder for concentrate for solution for infusion (Adcetris®)	2229	The treatment of adult patients with CD30+ cutaneous T-cell lymphoma (CTCL) after at least one prior systemic therapy. **SMC restriction:** for the treatment of patients with advanced CTCL, defined as mycosis fungoides stage IIB and above, primary cutaneous anaplastic large cell lymphoma or Sézary Syndrome.	Routinely available in line with national guidance, SMC 2229 https://www.scottishmedicines.org.uk/media/4980/brentuximab-vedotin-adcetris-final-december-2019-for-website.pdf Updates decision 21/01/20	16/06/2020

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
brigatinib 30mg, 90mg, 180mg film-coated tablets (Alunbrig®)	2147	As monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (ALK) positive advanced non-small cell lung cancer (NSCLC) previously treated with crizotinib.	Routinely available in line with national guidance, SMC 2147 https://www.scottishmedicines.org.uk/media/4449/brigatinib-alunbrig-final-may-2109-for-website.pdf Updates decision 18/06/19	18/08/2020
buprenorphine 8mg, 16mg, 24mg, 32mg, 64mg, 96mg, 128mg prolonged-release solution for injection (Buvidal®)	2169	Treatment of opioid dependence within a framework of medical, social and psychological treatment. Treatment is intended for use in adults and adolescents aged 16 years or over. **SMC restriction:** use in patients in whom methadone is not suitable and for whom the use of buprenorphine is considered appropriate.	Routinely available in line with national guidance, SMC 2169 https://www.scottishmedicines.org.uk/media/5962/buprenorphine-buvidal-final-july-2019-amended-180521-for-website.pdf Updates decision 20/08/19	21/04/2020
cariprazine 1.5mg, 3mg, 4.5mg, 6mg hard capsules (Reagila®)	2137	For the treatment of schizophrenia in adult patients. **SMC restriction:** for use as a second-line therapy in patients where predominantly negative symptoms have been identified as an important feature.	Routinely available in line with local guidance Updates decision 21/05/19	20/04/2021
cemiplimab 350mg concentrate for solution for infusion (Libtayo®)	2216	As monotherapy for the treatment of adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma (CSCC) who are not candidates for curative surgery or curative radiation.	Routinely available in line with national guidance, on an interim basis subject to ongoing evaluation and future reassessment, SMC 2216 https://www.scottishmedicines.org.uk/media/5069/cemiplimab-libtayo-final-jan-2020-for-website.pdf Updates decision 18/02/20	21/07/2020
certolizumab pegol 200mg solution for injection in pre-filled syringe and pen (Cimzia®)	2132	For the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy **SMC restriction:** patients who have failed to respond to standard systemic therapies (including ciclosporin, methotrexate and phototherapy), are intolerant to, or have a contraindication to these treatments.	Routinely available in line with national guidance, SMC 2132 https://www.scottishmedicines.org.uk/media/4326/certolizumab-pegol-cimzia-final-march-2019-amended-040419-for-website.pdf Updates decision 16/04/19	21/01/2020

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
chenodeoxycholic acid 250mg hard capsules (Chenodeoxycholic acid Leadiant®)	2190	For the treatment of inborn errors of primary bile acid synthesis due to sterol 27 hydroxylase deficiency (presenting as cerebrotendinous xanthomatosis) in infants, children and adolescents aged 1 month to 18 years and adults.	Not routinely available as not recommended for use in NHS Scotland, SMC 2190 https://www.scottishmedicines.org.uk/media/4380/chenodeoxycholic-acid-leadiant-non-sub-april-2019-for-website.pdf	21/05/2019
cinacalcet hydrochloride 1mg, 2.5mg, 5mg granules in capsules for opening (Mimpara®)	2275	Secondary hyperparathyroidism (HPT) Treatment of secondary HPT in adult patients with end-stage renal disease (ESRD) on maintenance dialysis therapy Treatment of secondary HPT in children aged 3 years and older with ESRD on maintenance dialysis therapy in whom secondary HPT is not adequately controlled with standard of care therapy Parathyroid carcinoma and primary HPT in adults Reduction of hypercalcaemia in adult patients with: - parathyroid carcinoma - primary HPT for whom parathyroidectomy would be indicated on the basis of serum calcium levels (as defined by relevant treatment guidelines), but in whom parathyroidectomy is not clinically appropriate or is contraindicated	Not routinely available as not recommended for use in NHS Scotland, SMC 2275 https://www.scottishmedicines.org.uk/media/5144/cinacalcet-mimpara-non-sub-final-february-2020-for-website.pdf	17/03/2020
clostridium botulinum neurotoxin type A 50units, 100units, 200units powder for solution for injection (Xeomin®)	2212	For the symptomatic treatment of chronic sialorrhoea due to neurological disorders in adults.	Routinely available in line with national guidance, SMC 2212 https://www.scottishmedicines.org.uk/media/4880/clostridium-botulinum-neurotoxin-type-a-xeomin-final-october-2019-for-website.pdf Updates decision 19/11/19	19/05/2020

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
dacomitinib 15mg, 30mg, 45mg film-coated tablets (Vizimpro®)	2184	As monotherapy, for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR)-activating mutations.	Routinely available in line with national guidance, SMC 2184 https://www.scottishmedicines.org.uk/media/4706/dacomitinib-vizimpro-final-august-2019-for-website.pdf Updates decision 17/09/19	18/08/2020
dapagliflozin 5mg film coated tablets (Forxiga®)	2185	In adults for the treatment of insufficiently controlled type 1 diabetes mellitus as an adjunct to insulin in patients with BMI ≥27kg/m^2, when insulin alone does not provide adequate glycaemic control despite optimal insulin therapy.	Not routinely available in NHS Grampian. Effective 25th October 2021 dapagliflozin 5mg is no longer authorised for the treatment of patients with type 1 diabetes mellitus (T1DM) and should no longer be used in this population. This is based on AstraZeneca's decision to remove the T1DM indication for dapagliflozin 5mg. Updates decision 17/09/19	16/11/2021
daratumumab 20mg/mL concentrate for solution for infusion (Darzalex®)	2180	In combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. **SMC restriction:** in combination with bortezomib and dexamethasone, for the treatment of adult patients with multiple myeloma who have received one prior therapy only.	Routinely available in line with national guidance, SMC 2180 https://www.scottishmedicines.org.uk/media/4531/daratumumab-darzalex-final-june-2019-for-website.pdf Updates decision 16/07/19	18/02/2020
daratumumab 20mg/mL concentrate for solution for infusion (Darzalex®)	2191	In combination with bortezomib, melphalan and prednisone for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant.	Not routinely available as not recommended for use in NHS Scotland, SMC 2191 https://www.scottishmedicines.org.uk/media/4381/daratumumab-darzalex-non-sub-final-april-2019-for-website.pdf	21/05/2019
daratumumab 20mg/mL concentrate for solution for infusion (Darzalex®)	2269	In combination with lenalidomide and dexamethasone for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant.	Not routinely available as not recommended for use in NHS Scotland, SMC 2269 https://www.scottishmedicines.org.uk/media/5058/daratumumab-daralez-non-sub-final-jan-2020-for-website.pdf	18/02/2020

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
darvadstrocel 30million cells/6mL suspension for injection (Alofisel®)	2115	For the treatment of complex perianal fistulas in adult patients with non-active / mildly active luminal Crohn's disease, when fistulas have shown an inadequate response to at least one conventional or biologic therapy.	This medicine is now withdrawn from use/discontinued Updates decision 16/07/19	21/03/2023
dasatinib 20mg, 50mg, 80mg, 100mg, 140mg film-coated tablets (Sprycel®)	2142	For the treatment of paediatric patients with newly diagnosed Philadelphia chromosome positive chronic myelogenous leukaemia in chronic phase (Ph+CML-CP) or Ph+ CML-CP resistant or intolerant to prior therapy including imatinib.	Routinely available in line with national guidance, SMC 2142 https://www.scottishmedicines.org.uk/media/4316/dasatinib-sprycel-abbreviated-final-march-2019-for-website.pdf	16/04/2019
dasatinib 20mg, 50mg, 80mg, 100mg, 140mg film-coated tablets (Sprycel®)	2192	For the treatment of paediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukaemia in combination with chemotherapy.	Not routinely available as not recommended for use in NHS Scotland, SMC 2192 https://www.scottishmedicines.org.uk/media/4514/dasatinib-sprycel-non-sub-final-april-2019-for-website.pdf	21/05/2019
Dovato® 50mg/300mg film-coated tablets (dolutegravir/lamivudine)	2205	Treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults and adolescents above 12 years of age weighing at least 40kg, with no known or suspected resistance to the integrase inhibitor class, or lamivudine.	Routinely available in line with national guidance, SMC 2205 https://www.scottishmedicines.org.uk/media/4708/dolutegravir-plus-lamivudine-dovato-abbreviated-final-august-2019-for-website.pdf	17/09/2019
dupilumab 200mg, 300mg solution for injection in pre-filled syringe (Dupixent®)	2232	The treatment of moderate-to-severe atopic dermatitis in adolescents aged 12 to <18 years who are candidates for systemic therapy. **SMC restriction:** patients who have had an inadequate response to existing systemic immunosuppressants such as ciclosporin, or in whom such treatment is considered unsuitable.	Routinely available in line with national guidance, SMC 2232 https://www.scottishmedicines.org.uk/media/4976/dupilumab-dupixent-abbreviated-final-december-2019-for-website.pdf	21/01/2020

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
durvalumab 50mg/mL concentrate for solution for infusion (Imfinzi®)	2156	As monotherapy for the treatment of locally advanced, unresectable non-small cell lung cancer (NSCLC) in adults whose tumours express PD-L1 [programmed cell death ligand 1] on ≥1% of tumour cells and whose disease has not progressed following platinum-based chemoradiation therapy.	Routinely available in line with national guidance, SMC 2156 https://www.scottishmedicines.org.uk/media/4450/durvalumab-imfinzi-final-may-2019-amended-14519-for-website.pdf Updates decision 18/06/19	16/07/2019
eculizumab 300mg concentrate for solution for infusion (Soliris®)	2236	Treatment of adults with refractory generalised myasthenia gravis who are anti-acetylcholine receptor antibody-positive.	Not routinely available as not recommended for use in NHS Scotland, SMC 2236 https://www.scottishmedicines.org.uk/media/4778/eculizumab-soliris-non-sub-final-sept-2019-for-website.pdf	19/11/2019
encorafenib 50mg, 75mg hard capsules (Braftovi®)	2238	In combination with binimetinib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.	Routinely available in line with national guidance, SMC 2238 https://www.scottishmedicines.org.uk/media/5051/encorafenib-braftovi-final-jan-2020-for-website.pdf Updates decision 18/02/20	18/08/2020
enzalutamide 40mg soft capsules (Xtandi®)	2195	The treatment of adult men with high-risk non-metastatic castration-resistant prostate cancer (CRPC).	Not routinely available as not recommended for use in NHS Scotland, SMC 2195 https://www.scottishmedicines.org.uk/media/4779/enzalutamide-xtandi-final-sept-2019-for-website.pdf	19/11/2019
erenumab 70mg solution for injection in pre-filled pen (Aimovig®)	2134	For the prophylaxis of migraine in adults who have at least four migraine days per month. **SMC restriction:** patients with chronic migraine and in whom at least three prior prophylactic treatments have failed.	Routinely available in line with local guidance Updates decision 16/04/19	16/07/2019
eribulin 0.44mg/mL solution for injection (Halaven®)	2231	Treatment of adult patients with unresectable liposarcoma who have received prior anthracycline containing therapy (unless unsuitable) for advanced or metastatic disease.	Not routinely available as not recommended for use in NHS Scotland, SMC 2231 https://www.scottishmedicines.org.uk/media/4714/eribulin-halaven-non-sub-final-august-2019-for-website.pdf	17/09/2019

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
fingolimod 0.25mg, 0.5mg hard capsules (Gilenya®)	2154	As a single disease modifying therapy in highly active relapsing remitting multiple sclerosis for the following groups of patients aged 10 to <18 years: 1) Patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy. or 2) Patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by two or more disabling relapses in one year, and with one or more gadolinium enhancing lesions on brain MRI or a significant increase in T2 lesion load as compared to a previous MRI.	Routinely available in line with national guidance, SMC 2154 https://www.scottishmedicines.org.uk/media/4443/fingolimod-gilenya-abbreviated-final-april-2019-for-website.pdf	18/06/2019
Fixapost® 50micrograms/mL / 5mg/mL preservative free eye drops (latanoprost/timolol)	2159	Reduction of intraocular pressure (IOP) in patients with open angle glaucoma and ocular hypertension who are insufficiently responsive to topical beta-blockers or prostaglandin analogues. **SMC restriction**: to use in patients who have proven sensitivity to preservatives.	Routinely available in line with national guidance, SMC 2159 https://www.scottishmedicines.org.uk/media/4384/latanoprost-plus-timolol-fixapost-abbreviated-final-april-2019-for-website.pdf Updates decision 21/05/19	16/11/2021
flutiform® 50microgram/5microgram metered dose inhaler (fluticasone propionate/formoterol fumarate)	2178	The regular treatment of asthma in children aged 5 to 12 years where the use of a combination product (an inhaled corticosteroid and a long-acting beta2 agonist) is appropriate: - For patients not adequately controlled with inhaled corticosteroids and 'as required' inhaled short-acting beta2 agonist or - For patients already adequately controlled on both an inhaled corticosteroid and a long-acting beta2 agonist.	Routinely available in line with national guidance, SMC 2178 https://www.scottishmedicines.org.uk/media/4444/fluticasone-formoterol-flutiform-abbreviated-final-may-2019-for-website.pdf	18/06/2019

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
fremanezumab 225mg solution for injection in prefilled syringe (Ajovy®)	2226	For prophylaxis of migraine in adults who have at least four migraine days per month. **SMC restriction:** for the treatment of patients with chronic and episodic migraine who have had prior failure on three or more migraine preventive treatments.	Routinely available in line with local guidance, Updates decision 21/01/20	21/04/2020
glibenclamide 0.6mg/mL, 6mg/mL oral suspension (Amglidia®)	2237	Treatment of neonatal diabetes mellitus, for use in newborns, infants and children.	Not routinely available as not recommended for use in NHS Scotland, SMC 2237 https://www.scottishmedicines.org.uk/media/4780/glibenclamide-amglidia-non-sub-final-sept-2019-for-website.pdf	19/11/2019
Glyxambi® 10mg/5mg, 25mg/5mg film-coated tablets (empagliflozin/linagliptin)	1236/17	In adults aged 18 years and older with type 2 diabetes mellitus: - to improve glycaemic control when metformin and/or sulphonylurea (SU) and one of the monocomponents of Glyxambi® do not provide adequate glycaemic control - when already being treated with the free combination of empagliflozin and linagliptin **SMC restriction:** restricted to use in line with the previous SMC advice on empagliflozin and linagliptin.	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time	20/08/2019
golimumab 50mg solution for injection in pre-filled pen, pre-filled syringe (Simponi®)	2203	In combination with methotrexate for the treatment of polyarticular juvenile idiopathic arthritis in children 2 years of age and older who have responded inadequately to previous therapy with methotrexate.	Not routinely available as not recommended for use in NHS Scotland, SMC 2203 https://www.scottishmedicines.org.uk/media/4445/golimumab-simponi-non-sub-final-may-2019-for-website.pdf	18/06/2019
ibrutinib 140mg hard capsules, 140mg, 280mg, 420mg, 560mg film-coated tablets (Imbruvica®)	2244	In combination with obinutuzumab for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia.	Not routinely available as not recommended for use in NHS Scotland, SMC 2244 https://www.scottishmedicines.org.uk/media/4882/ibrutinib-imbruvica-non-sub-final-oct-2019-for-website.pdf	19/11/2019

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
imiquimod 3.75% cream (Zyclara®)	2211	For the topical treatment of clinically typical, nonhyperkeratotic, nonhypertrophic, visible or palpable actinic keratosis of the full face or balding scalp in immunocompetent adults when other topical treatment options are contraindicated or less appropriate. **SMC restriction:** for the treatment of large field actinic keratosis (> 25cm^2).	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time Updates decision 19/11/19	20/10/2020
inotersen 284mg solution for injection in pre-filled syringe (Tegsedi®)	2188	For the treatment of stage 1 or stage 2 polyneuropathy in adult patients with hereditary transthyretin amyloidosis (hATTR).	Not routinely available in NHS Grampian. If local need identified treatment is available through the National Services Scotland Ultra orphan medicines Risk Share Scheme. Updates decision 20/08/19	21/07/2020
lanadelumab 300mg solution for injection (Takhzyro®)	2206	For the routine prevention of recurrent attacks of hereditary angioedema (HAE) in patients aged 12 years and older. **SMC restriction:** patients with HAE type I or II, who would otherwise be considered for long-term prophylaxis treatment with C1-esterase inhibitor.	Routinely available in line with national guidance, SMC 2206 https://www.scottishmedicines.org.uk/media/4947/lanadelumab-takhzyro-final-november-2019-for-website.pdf Updates decision 17/12/19	19/05/2020
lenalidomide 2.5mg, 5mg, 7.5mg, 10mg, 15mg, 20mg, 25mg hard capsules (Revlimid®)	2217	As combination therapy with bortezomib and dexamethasone for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for transplant.	Not routinely available as not recommended for use in NHS Scotland, SMC 2217 https://www.scottishmedicines.org.uk/media/4627/lenalidomide-revlimid-non-sub-final-july-2019-for-website.pdf	20/08/2019
lenvatinib 4mg hard capsules (Lenvima®)	2138	As monotherapy for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma who have received no prior systemic therapy.	Routinely available in line with national guidance, SMC 2138 https://www.scottishmedicines.org.uk/media/4318/lenvatinib-lenvima-final-march-2019-for-website.pdf Updates decision 16/04/19	20/08/2019

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
lenvatinib 4mg, 10mg hard capsules (Kisplyx®)	2199	In combination with everolimus for the treatment of adult patients with advanced renal cell carcinoma (RCC) following one prior vascular endothelial growth factor (VEGF)-targeted therapy.	Not routinely available as there is a local preference for alternative medicines, Updates decision 19/11/19	21/06/2022
lorlatinib 25mg, 100mg film-coated tablets (Lorviqua®)	2239	As monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) whose disease has progressed after: - alectinib or ceritinib as the first ALK tyrosine kinase inhibitor (TKI) therapy; or - crizotinib and at least one other ALK TKI	Routinely available in line with national guidance, on an interim basis subject to ongoing evaluation and future reassessment, SMC 2239 https://www.scottishmedicines.org.uk/media/5145/lorlatinib-lorviqua-final-february-2020-for-website.pdf Updates decision 17/03/20	18/08/2020
lusutrombopag 3mg film-coated tablets (Mulpleo®)	2227	For the treatment of severe thrombocytopenia in adult patients with chronic liver disease undergoing invasive procedures.	Not routinely available as there is a local preference for alternative medicines, Updates decision 17/12/19	16/03/2021
Maviret® 100mg/40mg film-coated tablets (glecaprevir/pibrentasvir)	2214	Treatment of chronic hepatitis C virus (HCV) infection in adolescents aged 12 to <18 years.	Routinely available in line with national guidance, SMC 2214 https://www.scottishmedicines.org.uk/media/4896/glecaprevir-pibrentasvir-maviret-abb-final-october-2019-for-website.pdf	19/11/2019
mepolizumab 100mg powder for solution for injection (Nucala®)	2139	As an add-on treatment for severe refractory eosinophilic asthma in adolescents and children aged 6 years to <18 years. **SMC restriction**: patients who have eosinophils of at least 150 cells per microlitre (0.15×10^9/L) at initiation of treatment and have had at least four asthma exacerbations in the preceding year or are receiving maintenance treatment with oral corticosteroids.	Routinely available in line with national guidance, SMC 2139 https://www.scottishmedicines.org.uk/media/4319/mepolizumab-nucala-abbreviated-final-march-2019-for-website.pdf	16/04/2019

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
nivolumab 10mg/mL concentrate for solution for infusion (Opdivo®)	2153	In combination with ipilimumab for the first-line treatment of adult patients with intermediate/poor-risk advanced renal cell carcinoma (RCC).	Routinely available in line with national guidance, SMC 2153 https://www.scottishmedicines.org.uk/media/4464/nivolumab-opdivo-final-may-2019-amended-030619-for-website.pdf Updates decision 18/06/19	17/03/2020
ocrelizumab 300mg concentrate for solution for infusion (Ocrevus®)	2223	For the treatment of adult patients with early primary progressive multiple sclerosis (PPMS) in terms of disease duration and level of disability, and with imaging features characteristic of inflammatory activity.	Routinely available in line with national guidance, SMC 2223 https://www.scottishmedicines.org.uk/media/4978/ocrelizumab-ocrevus-final-december-2019-for-website.pdf Updates decision 21/01/20	19/05/2020
olaparib 100mg, 150mg film-coated tablets (Lynparza®)	2209	As monotherapy for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy.	Routinely available in line with national guidance, SMC 2209 https://www.scottishmedicines.org.uk/media/4940/olaparib-lynparza-final-november-2019-for-website.pdf Updates decision 17/12/19	16/06/2020
Orkambi® 100mg/125mg, 200mg/125mg film-coated tablets, 100mg/125mg, 150mg/188mg granules in sachets (lumacaftor/ivacaftor)	2182	The treatment of cystic fibrosis in patients aged 6 years and older (tablets) and aged 2 to 5 years (granules) who are homozygous for the F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.	Not routinely available as not recommended for use in NHS Scotland, SMC 2182 https://www.scottishmedicines.org.uk/media/4652/lumacaftor-ivacaftor-orkambi-revised-final-july-2019-for-website.pdf	20/08/2019
ospemifene 60mg film-coated tablets (Senshio®)	2170	Treatment of moderate to severe symptomatic vulvar and vaginal atrophy (VVA) in post-menopausal women who are not candidates for local vaginal oestrogen therapy.	Routinely available in line with national guidance, https://www.scottishmedicines.org.uk/media/4711/ospemifene-senshio-final-august-2019-for-website.pdf Updates decision 17/09/19	19/05/2020

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
palbociclib 75mg, 100mg, 125mg hard capsules (Ibrance®)	2149	For the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer: - in combination with an aromatase inhibitor; - in combination with fulvestrant in women who have received prior endocrine therapy. In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinizing hormone-releasing hormone (LHRH) agonist.	Routinely available in line with national guidance, SMC 2149 https://www.scottishmedicines.org.uk/media/4533/palbociclib-ibrance-final-june-2019-for-website.pdf Updates decision 16/07/19	19/11/2019
patisiran 2mg/mL concentrate for solution for infusion (Onpattro®)	2157	Treatment of hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis) in adult patients with stage 1 or stage 2 polyneuropathy.	Not routinely available in NHS Grampian. If local need identified treatment is available through the National Services Scotland Ultra orphan medicines Risk Share Scheme. Updates decision 18/06/19	21/07/2020
pembrolizumab 25mg/mL concentrate for solution for infusion, 50mg powder for concentrate for solution for infusion (Keytruda®)	2144	As monotherapy for the adjuvant treatment of adults with Stage III melanoma and lymph node involvement who have undergone complete resection.	Routinely available in line with national guidance, SMC 2144 https://www.scottishmedicines.org.uk/media/4385/pembrolizumab-keytruda-final-april-2019-for-website.pdf Updates decision 21/05/19	18/06/2019
pembrolizumab 25mg/mL concentrate for solution for infusion, 50mg powder for concentrate for solution for infusion (Keytruda®)	2187	In combination with carboplatin and either paclitaxel, for the first-line treatment of metastatic squamous non-small cell lung cancer (NSCLC) in adults. **SMC restriction:** in patients whose tumours express programmed death ligand 1 (PD-L1) with a <50% tumour proportion score (TPS), or in those whom it has not been possible to evaluate PD-L1 TPS. Treatment with pembrolizumab is subject to a two-year clinical stopping rule.	Routinely available in line with national guidance, SMC 2187 https://www.scottishmedicines.org.uk/media/4717/pembrolizumab-keytruda-nsclc-final-august-2019-for-website.pdf Updates decision 17/09/19	18/08/2020

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
pembrolizumab 25mg/mL concentrate for solution for infusion, 50mg powder for concentrate for solution for infusion (Keytruda®)	2207	In combination with pemetrexed and platinum chemotherapy, for the first-line treatment of metastatic non-squamous non-small cell lung carcinoma (NSCLC) in adults whose tumours have no EGFR or ALK positive mutations. **SMC restriction:** in patients whose tumours express programmed death ligand 1 (PD-L1) with a <50% tumour proportion score (TPS), or in those whom it has not been possible to evaluate PD-L1 TPS. Treatment with pembrolizumab is subject to a two-year clinical stopping rule.	Routinely available in line with national guidance, SMC 2207 https://www.scottishmedicines.org.uk/media/4781/pembrolizumab-keytruda-resub-final-sept-2019-for-website.pdf Updates decision 19/11/19	18/08/2020
pentosan polysulfate sodium 100mg hard capsules (Elmiron®)	2194	For the treatment of bladder pain syndrome characterised by either glomerulations or Hunner's lesions in adults with moderate to severe pain, urgency and frequency of micturition.	Routinely available in line with national guidance, SMC 2194 https://www.scottishmedicines.org.uk/media/4886/pentosan-elmiron-final-october-2019-for-website.pdf Updates decision 19/11/19	20/07/2021
perampanel 0.5mg/mL oral suspension (Fycompa®)	2172	For the adjunctive treatment of partial-onset seizures with or without secondarily generalised seizures in adult and adolescent patients from 12 years of age with epilepsy. **SMC restriction:** use as a second-line adjunctive treatment in patients with refractory partial onset epilepsy who are unable to swallow perampanel tablets. Treatment should be initiated only by physicians who have appropriate experience in the treatment of epilepsy.	Routinely available in line with national guidance, SMC 2172 https://www.scottishmedicines.org.uk/media/4646/perampanel-fycompa-abbreviated-final-july-2019-for-website.pdf	20/08/2019
perampanel 0.5mg/mL oral suspension (Fycompa®)	2218	For the adjunctive treatment of primary generalised tonic-clonic seizures in adult and adolescent patients from 12 years of age with idiopathic generalised epilepsy.	Not routinely available as not recommended for use in NHS Scotland, SMC 2218 https://www.scottishmedicines.org.uk/media/4628/perampanel-fycompa-non-sub-final-july-2019-for-website.pdf	20/08/2019

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
plerixafor 20mg/mL solution for injection (Mozobil®)	2249	In combination with granulocyte-colony stimulating factor (G-CSF) to enhance mobilisation of haematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in children aged 1 year to <18 years with lymphoma or solid malignant tumours, either: - pre-emptively, when circulating stem cell count on the predicted day of collection after adequate mobilisation with G-CSF (with or without chemotherapy) is expected to be insufficient with regards to desired hematopoietic stem cells yield, or - who previously failed to collect sufficient haematopoietic stem cells.	Routinely available from a specialist centre in another health board	18/02/2020
pomalidomide 1mg, 2mg, 3mg, 4mg hard capsules (Imnovid®)	2219	In combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior treatment regimen including lenalidomide.	Not routinely available as not recommended for use in NHS Scotland, SMC 2219 https://www.scottishmedicines.org.uk/media/4629/pomalidomide-imnovid-non-sub-final-july-2019-for-website.pdf	20/08/2019
prasterone 6.5mg pessary (Intrarosa®)	2255	For the treatment of vulvar and vaginal atrophy in postmenopausal women having moderate to severe symptoms.	Not routinely available as not recommended for use in NHS Scotland, SMC 2255 https://www.scottishmedicines.org.uk/media/4941/prasterone-intrarosa-non-sub-final-november-2019-for-website.pdf	17/12/2019
ramucirumab 10mg/mL concentrate for solution for infusion (Cyramza®)	2246	As monotherapy for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma who have a serum alpha fetoprotein of ≥ 400 ng/mL and who have been previously treated with sorafenib.	Not routinely available as not recommended for use in NHS Scotland, SMC 2246 https://www.scottishmedicines.org.uk/media/4887/ramucirumab-cyramza-non-sub-final-october-2019-for-website.pdf	19/11/2019

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
ranibizumab 10mg/mL solution for injection (Lucentis®)	2274	In preterm infants for the treatment of retinopathy of prematurity (ROP) with zone I (stage 1+, 2+, 3 or 3+), zone II (stage 3+) or AP-ROP (aggressive posterior ROP) disease.	Not routinely available as not recommended for use in NHS Scotland, SMC 2274 https://www.scottishmedicines.org.uk/media/5146/ranibizumab-lucentis-non-sub-final-feb-2020-for-website.pdf	17/03/2020
ranibizumab 10mg/mL solution for injection, 10mg/mL solution for injection in pre-filled syringe (Lucentis®)	2270	Treatment of proliferative diabetic retinopathy in adults.	Not routinely available as not recommended for use in NHS Scotland, SMC 2270 https://www.scottishmedicines.org.uk/media/5053/ranibizumab-lucentis-non-sub-final-jan-2020-for-website.pdf	18/02/2020
ribociclib 200mg film-coated tablets (Kisqali®)	2198	For the treatment of women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in combination with fulvestrant* as initial endocrine-based therapy, or in women who have received prior endocrine therapy. **SMC restriction:** women who have relapsed on or within 12 months of completing (neo) adjuvant endocrine therapy, or those who have progressed on first-line endocrine-based therapy for advanced breast cancer.	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time	19/11/2019
risankizumab 75mg solution for injection in pre-filled syringe (Skyrizi®)	2196	For the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. **SMC restriction:** for patients who have failed to respond to conventional systemic therapies (including ciclosporin, methotrexate and	Routinely available in line with national guidance, SMC 2196 https://www.scottishmedicines.org.uk/media/4775/risankizumab-skyrizi-final-sept-2019-amended-20919-for-website.pdf Risankizumab 75mg pre-filled syringes have been discontinued and replaced by 150mg pre-filled syringes. The	21/01/2020

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
rituximab 100mg concentrate for solution for infusion (MabThera®)	2193	For the treatment of patients with moderate to severe pemphigus vulgaris.	Not routinely available as not recommended for use in NHS Scotland, SMC 2193 https://www.scottishmedicines.org.uk/media/4386/rituximab-mabthera-non-sub-final-april-2019-for-website.pdf	21/05/2019
rucaparib 200mg, 250mg, 300mg film-coated tablets (Rubraca®)	2221	As monotherapy treatment of adult patients with platinum sensitive, relapsed or progressive, BRCA mutated (germline and/or somatic), high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have been treated with two or more prior lines of platinum based chemotherapy, and who are unable to tolerate further platinum based chemotherapy.	Not routinely available in NHS Grampian. The September 2022 Drug Safety Update article advises that the third-line treatment indication for rucaparib has been withdrawn following a review of the findings of the ARIEL-4 trial, which showed lower overall survival for rucaparib treatment versus standard chemotherapy in patients with high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer. Updates decision 20/08/19	18/10/2022
rucaparib 200mg, 250mg, 300mg film-coated tablets (Rubraca®)	2224	As monotherapy for the maintenance treatment of adult patients with platinum-sensitive relapsed high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum-based chemotherapy. **SMC restriction:** to patients who do not have a BRCA mutation.	Routinely available in line with national guidance, SMC 2224 https://www.scottishmedicines.org.uk/media/5147/rucaparib-rubraca-final-february-2020-for-website.pdf Updates decision 17/03/20	15/12/2020
rufinamide 40mg/mL oral suspension, 100mg, 200mg, 400mg tablets (Inovelon®)	2146	As adjunctive therapy in the treatment of seizures associated with Lennox-Gastaut syndrome in patients aged 1 years to <4 years. **SMC restriction:** restricted to use in patients who have failed treatment with or are intolerant of other antiepileptic drugs.	Routinely available in line with national guidance, SMC 2146 https://www.scottishmedicines.org.uk/media/4355/rufinamide-inovelon-abbreviated-final-march-2019-revised-for-website.pdf	16/04/2019

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
ruxolitinib phosphate 5mg, 10mg, 15mg, 20mg tablets (Jakavi®)	2213	The treatment of adult patients with polycythaemia vera who are resistant to or intolerant of hydroxyurea (hydroxycarbamide).	Routinely available in line with national guidance, SMC 2213 https://www.scottishmedicines.org.uk/media/4942/ruxolitinib-jalkavi-final-november-2019-for-website.pdf Updates decision 17/12/19	19/05/2020
Symkevi® 100mg/150mg film-coated tablets (tezacaftor/ivacaftor)	2183	In a combination regimen with ivacaftor 150mg tablets for the treatment of patients with cystic fibrosis (CF) aged 12 years and older who are homozygous for the F508del mutation or who are heterozygous for the F508del mutation and have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: P67L, R117C, L206W, R352Q, A455E, D579G, 711+3A→G, S945L, S977F, R1070W, D1152H, 2789+5G→A, 3272-26A→G, and 3849+10kbC→T.	Not routinely available as not recommended for use in NHS Scotland, SMC 2183 https://www.scottishmedicines.org.uk/media/4643/tezacaftor-ivacaftor-symkevi-final-july-2019-for-website.pdf	20/08/2019
teduglutide 5mg vial of powder and solvent for solution for injection (Revestive®)	2225	For the treatment of adult patients with short bowel syndrome (SBS). Patients should be stable following a period of intestinal adaptation after surgery.	Routinely available in line with national guidance, SMC 2225 https://www.scottishmedicines.org.uk/media/5054/teduglutide-revestive-resub-final-jan-2020-for-website.pdf	18/02/2020
testosterone 20mg/g transdermal gel (Testavan®)	2152	Testosterone replacement therapy for adult male hypogonadism, when testosterone deficiency has been confirmed by clinical features and biochemical tests. **SMC restriction:** patients requiring a transdermal delivery system.	Routinely available in line with national guidance, SMC 2152 https://www.scottishmedicines.org.uk/media/4425/testosterone-testavan-abbreviated-final-march-2019-for-website-updated-240519.pdf Updates decision 16/04/19	21/05/2019

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
tildrakizumab 100mg solution for injection in prefilled syringe (Ilumetri®)	2167	The treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy. **SMC restriction:** for use in patients who have failed to respond to conventional systemic therapies (including ciclosporin, methotrexate and phototherapy), are intolerant to, or have a contraindication to these treatments.	Routinely available in line with national guidance, SMC 2167 https://www.scottishmedicines.org.uk/media/4645/tildrakizumab-ilumetri-final-july-amended-020819-for-website.pdf Updates decision 20/08/19	21/01/2020
tisagenlecleucel 1.2 x 10^6 - 6 x 10^8 cells dispersion for infusion (Kymriah®)	2200	Adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy.	Routinely available from a specialist centre in another health board, SMC 2200 https://www.scottishmedicines.org.uk/media/4713/tisagenlecleucel-kymriah-final-august-2019-amended-3919-for-website.pdf	17/09/2019
trientine tetrahydrochloride (equivalent to 150mg trientine) film-coated tablets (Cuprior®)	2222	The treatment of Wilson's disease in adults, adolescents and children ≥5 years intolerant to D-penicillamine therapy.	Routinely available in line with local guidance Updates decision 19/11/19	16/06/2020
triptorelin sustained-release 3mg powder for suspension for injection (Decapeptyl SR®)	2186	As adjuvant treatment in combination with tamoxifen or an aromatase inhibitor, of endocrine responsive early stage breast cancer in women at high risk of recurrence who are confirmed as premenopausal after completion of chemotherapy.	Not routinely available as the ADTC is waiting for further advice from local clinical experts	19/11/2019
venetoclax 10mg, 50mg, 100mg film-coated tablets (Venclyxto®)	2166	In combination with rituximab for the treatment of adult patients with chronic lymphocytic leukaemia (CLL) who have received at least one prior therapy.	Routinely available in line with national guidance, SMC 2166 https://www.scottishmedicines.org.uk/media/4631/venetoclax-venclyxto-final-july-2019-for-website.pdf Updates decision 20/08/19	18/02/2020

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
Xonvea® 10mg/10mg gastro-resistant tablets (doxylamine succinate/pyridoxine hydrochloride)	2140	For the treatment of nausea and vomiting of pregnancy in women who do not respond to conservative management.	Not routinely available as not recommended for use in NHS Scotland, SMC 2140 https://www.scottishmedicines.org.uk/media/4452/doxylamine-succinate-pyridoxine-hydrochloride-xonvea-final-april-2019-for-website.pdf	21/05/2019
zanamivir 10mg/mL solution for infusion (Dectova®)	2204	For the treatment of complicated and potentially life-threatening influenza A or B virus infection in adult and paediatric patients (aged ≥6 months) when: - the patient's influenza virus is known or suspected to be resistant to anti-influenza medicinal products other than zanamivir, and/or - other antiviral medicinal products for treatment of influenza, including inhaled zanamivir, are not suitable for the individual patient.	Routinely available in line with national guidance, SMC 2204 https://www.scottishmedicines.org.uk/media/4944/zanamivir-dectova-abbreviated-final-august-2019-for-website.pdf	17/12/2019
Zerbaxa® 1g/0.5g powder for concentrate for solution for infusion (ceftolozane/tazobactam)	2256	In adults for the treatment of hospital acquired pneumonia, including ventilator-associated pneumonia.	Not routinely available as not recommended for use in NHS Scotland, SMC 2256 https://www.scottishmedicines.org.uk/media/4946/ceftolozane-tazobactam-zerbaxa-non-sub-final-november-2019-for-website.pdf	17/12/2019